Open Access

Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans‑arterial chemoembolization therapy

  • Authors:
    • Zhan‑Hong Chen
    • Ying‑Fen Hong
    • Xiangwei Chen
    • Jie Chen
    • Qu Lin
    • Jinxiang Lin
    • Xing Li
    • Jing‑Yun Wen
    • Dan‑Yun Ruan
    • Min Dong
    • Li Wei
    • Tian‑Tian Wang
    • Ze‑Xiao Lin
    • Xiao‑Kun Ma
    • Dong‑Hao Wu
    • Xiang‑Yuan Wu
    • Ruihua Xu
  • View Affiliations

  • Published online on: November 15, 2017     https://doi.org/10.3892/ol.2017.7419
  • Pages:855-862
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

The majority of patients with unresectable hepatocellular carcinoma (HCC) undergo trans‑arterial chemoembolization (TACE). However, the prognosis of HCC remains poor. In the present study, five staging systems were compared to predict the survival rate of patients with HCC undergoing TACE treatment. A total of 220 patients with HCC were examined according to the model to estimate survival for hepatocellular carcinoma (MESH), hepatoma arterial embolization prognostic score (HAP), modified HAP (mHAP), performance status combined Japan Integrated Staging system (PSJIS) and tumor‑node‑metastasis (TNM) staging systems. The endpoints of the study were 3‑month survival, 6‑month survival, 1‑year survival and overall survival (OS) rates. Receiver operating characteristic curve analysis indicated that the area under the curve of MESH, HAP, mHAP, PSJIS and TNM was 0.858, 0.728, 0.690, 0.688 and 0.699, respectively, in predicting 3‑month survival rates; 0.822, 0.747, 0.720, 0.722 and 0.715, respectively, in predicting 6‑month survival rates and 0.725, 0.664, 0.672, 0.645 and 0.654, respectively, in predicting 1‑year survival rates. Discriminatory ability, homogeneity, monotonicity and prognostic stratification ability was evaluated using a likelihood ratio test and Akaike information criterion values among the five staging systems, and revealed that the MESH system was the optimal prognostic staging system for HCC. In conclusion, the results of the present study suggest that the MESH system is the most accurate prognostic staging system of 3‑month survival, 6‑month survival, 1‑year survival and OS rates among the five systems analyzed in patients with HCC who have received TACE treatment.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Z., Hong, Y., Chen, X., Chen, J., Lin, Q., Lin, J. ... Xu, R. (2018). Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans‑arterial chemoembolization therapy. Oncology Letters, 15, 855-862. https://doi.org/10.3892/ol.2017.7419
MLA
Chen, Z., Hong, Y., Chen, X., Chen, J., Lin, Q., Lin, J., Li, X., Wen, J., Ruan, D., Dong, M., Wei, L., Wang, T., Lin, Z., Ma, X., Wu, D., Wu, X., Xu, R."Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans‑arterial chemoembolization therapy". Oncology Letters 15.1 (2018): 855-862.
Chicago
Chen, Z., Hong, Y., Chen, X., Chen, J., Lin, Q., Lin, J., Li, X., Wen, J., Ruan, D., Dong, M., Wei, L., Wang, T., Lin, Z., Ma, X., Wu, D., Wu, X., Xu, R."Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans‑arterial chemoembolization therapy". Oncology Letters 15, no. 1 (2018): 855-862. https://doi.org/10.3892/ol.2017.7419